ALPHA1-ANTITRYPSIN DEFICIENCY
Clinical trials for ALPHA1-ANTITRYPSIN DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ALPHA1-ANTITRYPSIN DEFICIENCY trials appear
Sign up with your email to follow new studies for ALPHA1-ANTITRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to stop liver scarring in Alpha-1 patients
Disease control Recruiting nowThis study tests a medicine called fazirsiran for people with liver disease caused by Alpha-1 antitrypsin deficiency. The drug works by reducing the buildup of an abnormal protein in the liver that can lead to scarring and liver failure. About 50 adults with mild liver scarring w…
Matched conditions: ALPHA1-ANTITRYPSIN DEFICIENCY
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 11:35 UTC
-
New drug could slow liver damage in rare genetic disease
Disease control Recruiting nowThis study tests an experimental drug called fazirsiran in 160 adults with Alpha-1 antitrypsin deficiency who have moderate to severe liver scarring (fibrosis). Participants receive either fazirsiran or a placebo, and doctors measure changes in liver scarring and other markers ov…
Matched conditions: ALPHA1-ANTITRYPSIN DEFICIENCY
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
500 adults with rare genetic condition to be tracked for liver changes
Knowledge-focused Recruiting nowThis study follows 500 adults with Alpha-1 Antitrypsin Deficiency (AATD) for up to 5 years to understand how liver disease naturally progresses without treatment. Researchers will track liver scarring, complications, and lung function, and use questionnaires to learn about partic…
Matched conditions: ALPHA1-ANTITRYPSIN DEFICIENCY
Sponsor: Takeda • Aim: Knowledge-focused
Last updated May 26, 2026 11:07 UTC